Association of Receipt of Fourth Pfizer-BioNTech Vaccine Dose With Omicron Infection, COVID-19 Hospitalizations Among Residents of Long-term Care Facilities

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JUNE 23, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2022.2658?guestAccessKey=5a1cc8de-6664-4251-9169-f771b4051360&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062322

 

About The Study: The results of this study suggest that receipt of a fourth dose of the Pfizer-BioNTech vaccine conferred high protection against COVID-19 hospitalizations and deaths among long-term care facility residents in Israel during a substantial Omicron variant surge but protection was modest against infection.

Authors: Khitam Muhsen, Ph.D., of Tel Aviv University in Tel Aviv, Israel, is the corresponding author.

 

(doi:10.1001/jamainternmed.2022.2658)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.